A Phase 1 interventional study of MSC2156119J in Solid Tumors, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-08-06.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Treatment
This is a Japanese multicenter, open-label, Phase 1 study to evaluate safety and efficacy of MSC2156119J in subjects with malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is applicable.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 12 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Merck KGaA, Darmstadt, Germany is the lead sponsor of 269 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: MSC2156119J
Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
Number of Subjects Experiencing Dose Limiting Toxicity (DLT)
DLT: defined using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0, as any of following toxicities: Grade 4 neutropenia for more than 7 days; greater than or equal to (\>=) Grade 3 febrile neutropenia; Grade 4 or Grade 3 thrombocytopenia with bleeding; \>=Grade 3 nausea despite adequate treatment; \>=Grade 3 any non-hematological AE (DLT defined specifically for following cases: \>=Grade 3 liver adverse event \[AE\] requiring recovery period of more than 7 days or to Grade 1 without liver metastases or Grade 2 with liver metastases ; \>=Grade 3 lipase and/or amylase elevation with confirmation of pancreatitis. An isolated lipase and/or amylase elevation of \>=Grade 3 without clinical/radiological evidence of pancreatitis was not classified as DLT); and \>=Grade 2 any AE not otherwise defined as DLT that, due to prolonged recovery to Grade 1 (or less) or baseline status, led to delay of treatment with IMP for more than 21 days.
Time frame: Cycle 1 (Day 1 up to 21)
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs or TEAEs Leading To Death
An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline Up to 30 days after last dose of study drug administration (55.1 weeks)
Number of Subjects With Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 2 or Higher
ECOG PS score is widely used by doctors and researchers to assess how a subjects' disease is progressing, and is used to assess how the disease affects the daily living abilities of the subject, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 4, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
Time frame: Baseline up to 30 days after last dose of study drug administration (55.1 weeks)
Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1
Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1
Time to Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1
Time to Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1
Apparent Terminal Half-life (t1/2) of MSC2156119J
Terminal half-life is the time measured for the plasma concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base 2 (Ln2) divided by elimination rate constant (λz), where 'λz' is calculated by a linear regression of the log-linear concentration-time curve.
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1 and Day 14 Cycle 1
Area Under the Concentration Time Curve From Time Zero to Extrapolated Infinite Time (AUC[Inf]) of MSC2156119J
AUC(inf) was calculated by combining AUC0-t and AUCextra. AUCextra represented an extrapolated value obtained by Clast/λz, where Clast was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLQ and λz is the terminal elimination rate constant.
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1 and Day 14 Cycle 1
Apparent Body Clearance (CL/f) of MSC2156119J
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. CL/F = Dose/AUC(inf), where AUC(inf) =AUC0-t + AUCextra. AUCextra represented an extrapolated value obtained by Clast/λz, where Clast was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLQ and λz is the terminal elimination rate constant.
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1 and Day 14 Cycle 1
Apparent Volume of Distribution Associated To The Terminal Phase (Vz/f) of MSC2156119J
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed and is calculated by Dose/(AUC(inf)\*λz).
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1 and Day 14 Cycle 1
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time t (AUC0-t) After Single Dose of MSC2156119J
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration is at or above the lower limit of quantification (LLQ) AUC0-t was calculated according to the mixed log-linear trapezoidal rule
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time t (AUC0-t) After Multiple Dose of MSC2156119J
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration is at or above the LLQ. AUC0-t was calculated according to the mixed log-linear trapezoidal rule
Time frame: pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1
Number of Subjects With Best Overall Response (BOR)
Number of subjects with BOR in each category (complete response \[CR\], partial response \[PR\], stable disease \[SD\], progressive disease \[PD\]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD: defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.
Time frame: Day 21 of Cycle 2 and each subsequent cycle up to a maximum of 51.1 weeks
Number of Subjects With Clinical Benefit
Clinical Benefit was defined as CR or PR at any time point or SD at week 12 or later, based on tumor assessment as determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study. PD: defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions.
Time frame: Day 21 of Cycle 2 and each subsequent cycle up to a maximum of 51.1 weeks
Progression-free Survival (PFS)
PFS was defined as the time in months from the first administration of trial treatment until first observation of progressive disease (PD), or death due to any cause when death occurs within 12 weeks of the last tumor assessment or first administration of trial treatment (whichever is later). Any subject with neither assessment of tumor progression, nor death within 12 weeks after last tumor assessment date was censored on the date of last tumor assessment. PFS was planned to be presented for "MSC2156119J Combined" reporting arm.
Time frame: Day 21 of Cycle 2 and each subsequent cycle up to a maximum of 51.1 weeks
First/last subject (informed consent): 15 April 2013/20 September 2013. Last subject completed: 22 October 2014.
| Milestone | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Started | 3 | 3 | 6 |
| Completed | 3 | 3 | 6 |
| Not completed | 0 | 0 | 0 |
DLT: defined using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0, as any of following toxicities: Grade 4 neutropenia for more than 7 days; greater than or equal to (\>=) Grade 3 febrile neutropenia; Grade 4 or Grade 3 thrombocytopenia with bleeding; \>=Grade 3 nausea despite adequate treatment; \>=Grade 3 any non-hematological AE (DLT defined specifically for following cases: \>=Grade 3 liver adverse event \[AE\] requiring recovery period of more than 7 days or to Grade 1 without liver metastases or Grade 2 with liver metastases ; \>=Grade 3 lipase and/or amylase elevation with confirmation of pancreatitis. An isolated lipase and/or amylase elevation of \>=Grade 3 without clinical/radiological evidence of pancreatitis was not classified as DLT); and \>=Grade 2 any AE not otherwise defined as DLT that, due to prolonged recovery to Grade 1 (or less) or baseline status, led to delay of treatment with IMP for more than 21 days.
| subjects | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Number of Subjects Experiencing Dose Limiting Toxicity (DLT) | 0 | 0 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.
| subjects | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| TEAEs | 2 | 3 | 6 |
| Serious TEAEs | 0 | 3 | 1 |
| TEAEs Leading To Death | 0 | 0 | 1 |
ECOG PS score is widely used by doctors and researchers to assess how a subjects' disease is progressing, and is used to assess how the disease affects the daily living abilities of the subject, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 4, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
| subjects | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Number of Subjects With Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 2 or Higher | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J | 244.4 ± 29.9 | 301.3 ± 42.6 | 442.4 ± 27.5 |
| ng/mL | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J | 807.5 ± 11.5 | 610.1 ± 84.8 | 996.8 ± 17.5 |
| hours | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J | 8.000 (7.92 to 8.03) | 8.017 (8.00 to 10.02) | 10.000 (3.97 to 23.85) |
| hours | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J | 8.000 (7.98 to 8.02) | 9.917 (1.95 to 10.23) | 4.133 (3.87 to 9.87) |
Terminal half-life is the time measured for the plasma concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base 2 (Ln2) divided by elimination rate constant (λz), where 'λz' is calculated by a linear regression of the log-linear concentration-time curve.
No measurements were reported for this outcome.
AUC(inf) was calculated by combining AUC0-t and AUCextra. AUCextra represented an extrapolated value obtained by Clast/λz, where Clast was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLQ and λz is the terminal elimination rate constant.
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. CL/F = Dose/AUC(inf), where AUC(inf) =AUC0-t + AUCextra. AUCextra represented an extrapolated value obtained by Clast/λz, where Clast was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLQ and λz is the terminal elimination rate constant.
No measurements were reported for this outcome.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed and is calculated by Dose/(AUC(inf)\*λz).
No measurements were reported for this outcome.
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration is at or above the lower limit of quantification (LLQ) AUC0-t was calculated according to the mixed log-linear trapezoidal rule
| h*ng/mL | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time t (AUC0-t) After Single Dose of MSC2156119J | 4060.8 ± 30.7 | 5412.7 ± 45.0 | 8235.0 ± 30.9 |
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration is at or above the LLQ. AUC0-t was calculated according to the mixed log-linear trapezoidal rule
| h*ng/mL | MSC2156119J 200 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time t (AUC0-t) After Multiple Dose of MSC2156119J | 16088.6 ± 12.2 | 13313.4 ± 82.5 | 21509.0 ± 16.7 |
Number of subjects with BOR in each category (complete response \[CR\], partial response \[PR\], stable disease \[SD\], progressive disease \[PD\]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD: defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.
| subjects | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| CR | 0 | 0 | 0 |
| PR | 0 | 0 | 0 |
| SD | 0 | 0 | 2 |
| PD | 3 | 3 | 3 |
| Not Evaluable | 0 | 0 | 1 |
Clinical Benefit was defined as CR or PR at any time point or SD at week 12 or later, based on tumor assessment as determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study. PD: defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions.
| subjects | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| Number of Subjects With Clinical Benefit | 0 | 0 | 2 |
PFS was defined as the time in months from the first administration of trial treatment until first observation of progressive disease (PD), or death due to any cause when death occurs within 12 weeks of the last tumor assessment or first administration of trial treatment (whichever is later). Any subject with neither assessment of tumor progression, nor death within 12 weeks after last tumor assessment date was censored on the date of last tumor assessment. PFS was planned to be presented for "MSC2156119J Combined" reporting arm.
| months | MSC2156119J Combined |
|---|---|
| Progression-free Survival (PFS) | 1.38 (1.15 to 1.38) |
Collected over Baseline Up to 30 days after last dose of study drug administration (55.1 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MSC2156119J 215 mg | — | 0/3 (0%) | 2/3 (66.7%) |
| MSC2156119J 300 mg | — | 3/3 (100%) | 3/3 (100%) |
| MSC2156119J 500 mg | — | 1/6 (16.7%) | 6/6 (100%) |
| Event | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 1/6 |
| MALAISEGeneral disorders | 0/3 | 1/3 | 0/6 |
| DECREASED APPETITEMetabolism and nutrition disorders | 0/3 | 1/3 | 0/6 |
| ALTERED STATE OF CONSCIOUSNESSNervous system disorders | 0/3 | 1/3 | 0/6 |
| Event | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg |
|---|---|---|---|
| FATIGUEGeneral disorders | 1/3 | 2/3 | 1/6 |
| OEDEMA PERIPHERALGeneral disorders | 0/3 | 0/3 | 4/6 |
| CONSTIPATIONGastrointestinal disorders | 1/3 | 2/3 | 3/6 |
| NAUSEAGastrointestinal disorders | 0/3 | 2/3 | 3/6 |
| HYPOALBUMINAEMIAMetabolism and nutrition disorders | 0/3 | 0/3 | 4/6 |
| VOMITINGGastrointestinal disorders | 0/3 | 1/3 | 3/6 |
| DECREASED APPETITEMetabolism and nutrition disorders | 1/3 | 1/3 | 3/6 |
| MALAISEGeneral disorders | 0/3 | 1/3 | 1/6 |
| VESSEL PUNCTURE SITE ERYTHEMAGeneral disorders | 1/3 | 0/3 | 0/6 |
| ASCITESGastrointestinal disorders | 0/3 | 1/3 | 0/6 |
Safety analysis set included all subjects who had received at least 1 dose of the investigational medicinal product (IMP).
| Age, Continuous(years) | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg | Total |
|---|---|---|---|---|
| Mean | 61.7 ± 9.6 | 62.0 ± 5.0 | 65.7 ± 9.8 | 63.8 ± 8.3 |
| Sex: Female, Male(Participants) | MSC2156119J 215 mg | MSC2156119J 300 mg | MSC2156119J 500 mg | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 2 | 4 |
| Male | 2 | 2 | 4 | 8 |
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck KGaA, Darmstadt, Germany